Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Merck’s KEYTRUDA Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Cervical Cancer

americanpharmaceuticalreviewJune 23, 2021

Tag: Merck , Keytruda , PD-L1 , Bevacizumab

PharmaSources Customer Service